Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Waters Corporation excels in Q3, eyes growth in key markets

Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.
Despite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.
With a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Waters Corp WAT reported fourth-quarter FY21 revenue growth of 8% year-on-year in CC to $836 million above the consensus of $821 million. [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ultimate Bear Market Survival Guide with Matt Maley!

Waters Tops Q4 Consensus; Issues Robust FY22 Outlook

Waters (WAT) delivered earnings and revenue surprises of 5.76% and 1.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Tops Q4 Earnings and Revenue Estimates

MILFORD, Mass.--(BUSINESS WIRE)---- $WAT #biopharma--Waters Corp. has acquired the technology assets and IP of Megadalton Solutions, Inc., a developer of Charge Detection Mass Spectrometry technology.

Waters Acquires Charge Detection Mass Spectrometry Technology to Broaden its Application in Cell and Gene Therapy

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced fourth quarter 2021 sales of $836 million, an increase of 6% as reported and 8% in constant currency, compared to sales of $787 million for the fourth quarter of 2020. On a GAAP basis, diluted earnings per share (EPS) for the fourth quarter of 2021 increased to $3.52, compared to $3.49 for the fourth quarter of 2020. On a non-GAAP basis, EPS increased to $3.67, compared to $3.65 for the fourth quarter of 2020. A des

Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2021 Financial Results

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced that it received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report, measuring corporate policies and practices related to LGBTQ+ workplace equality. “We are incredibly proud of the progress and achievements we've made towards creating an inclusive workplace where diversity in all forms can thrive — but our work is not done,” sa

Waters Earns Top Score in Human Rights Campaign Foundation's 2022 Corporate Equality Index

MILFORD, Mass.--(BUSINESS WIRE)-- #EmpowerCDS--U.S. Food and Drug Administration to deploy Waters Empower and NuGenesis software at its medical products testing labs.

U.S. Food and Drug Administration Expands Deployment of Waters Corporation Software to Support its Medical Products Testing Labs

Waters (WAT) releases the MS Quan application on the waters_connect informatics software platform to help scientists efficiently screen large number of samples and contaminants.

Waters (WAT) Boosts Mass Spectrometry Via MS Quan Application

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q4 2021 financial results conference call live on Tuesday, February 1st 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least February 15th, 2022 at midnight eastern time. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty meas

Waters Corporation Q4 2021 Financial Results Webcast Invitation

MILFORD, Mass.--(BUSINESS WIRE)-- #massspec--Waters accelerates quantitative mass spectrometry analyses with MS Quan, a new software application for the waters_connect informatics platform.

Waters Accelerates Quantitative Mass Spectrometry With New Application on waters_connect Informatics Platform

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the J.P. Morgan Healthcare Conference virtually on Monday, January 10th, 2022 at 8:15AM Eastern Standard Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will be available for 30 days. About Waters Corporation Waters Corpor

Waters Corporation Presentation at the 40th Annual J.P. Morgan Healthcare Conference to be Webcast Live

Intel

Lockheed Martin

Omnicom Group

Zimmer Biomet Hlds

In the third quarter of 2021, which ended on Sept. 30, U.S. stock markets kept marching steadily higher as the combination of easy monetary policy, economic recovery and inflation made stocks arguably the safest asset class to invest in.

The Most Popular Guru Buys of the 3rd Quarter

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Waters (WAT) Down 5.5% Since Last Earnings Report: Can It Rebound?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the Evercore ISI 4th Annual HealthCONx Healthcare Conference virtually on Tuesday, November 30th, 2021 at 12:10PM Eastern Standard Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters

Waters Corporation Presentation at the Evercore ISI HealthCONx 2021 Virtual Health Care Conference to Be Webcast Live

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today released its 2021 Sustainability Report, highlighting companywide achievements such as reductions in environmental impacts, supply chain enhancements and diversity and inclusion initiatives. In addition, the report covers Waters' COVID-19 response priorities that include ensuring the safety and well-being of its employees, helping to mitigate the public health crisis, and maintaining global business continuity. “As we look to

Waters' 2021 Sustainability Report Highlights Progress on ESG Initiatives and Response to COVID-19

Waters' (WAT) third-quarter results reflect gains from strong momentum across pharmaceutical and industrial end-markets.

Waters (WAT) Q3 Earnings & Revenues Beat Estimates, Rise Y/Y

Waters Corporation (WAT) CEO Udit Batra on Q3 2021 Results - Earnings Call Transcript

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced third quarter 2021 sales of $659 million, an 11% increase as reported, compared to sales of $594 million for the third quarter of 2020. Foreign currency translation benefited sales growth by less than 1% for the quarter. On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2021 increased to $2.60, compared to $2.03 for the third quarter of 2020. On a non-GAAP basis, EPS increased to $2.66, comp

Waters Corporation (NYSE: WAT) Reports Third Quarter 2021 Financial Results

Waters' (WAT) third-quarter 2021 results are likely to reflect strength across liquid chromatography instruments and mass spectrometers.

Waters (WAT) to Report Q3 Earnings: What's in the Cards?

MILFORD, Mass. & GOETTINGEN, Germany--(BUSINESS WIRE)-- #biologics--Waters and Sartorius Partner to Help Bioprocess Scientists Accelerate Clone Selection and Process Development

Waters and Sartorius Partner to Help Bioprocess Scientists Accelerate Clone Selection and Process Development

MILFORD, Mass. & NEWARK, Del.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) and the University of Delaware today announced a five-year research partnership to develop new analytical solutions for bioprocessing and biomanufacturing. Key to this partnership is Immerse™ Delaware, an Innovation and Research Lab, (“Immerse Delaware”) set to open in early 2022 located at the University of Delaware Science, Technology and Advanced Research (STAR) campus. At Immerse Delaware, Waters will partner with

Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q3 2021 financial results conference call live on Tuesday, November 2nd, 2021 at 8:00 a.m. eastern time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will be available until November 16th, 2021 at midnight eastern time. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty m

Waters Corporation Q3 2021 Financial Results Webcast Invitation

MILFORD, Mass.--(BUSINESS WIRE)---- $WAT #biopharma--Waters announces the appointment of John M. Ballbach to its Board of Directors and the retirement of Dr. Michael J. Berendt from the Waters BoD.

Waters Corporation Appoints John M. Ballbach to Board of Directors

Agilent Technologies

American Water Works

Invesco S&P Global Water Index ETF

Danaher

Ecolab

Ferguson Enterprises Inc

First Trust Water ETF

Invesco

Invesco Water Resources ETF

Invesco Global Water ETF

Pentair

Roper Technologies

Veolia Environnement SA

Xylem

An in-depth look at the leading water ETFs in the U.S stock market.

Investing in Water ETFs

Waters (WAT) introduces Waters BioAccord System with ACQUITY Premier for seamless monitoring of attributes of biotherapeutics.

Waters (WAT) BioAccord System to Expand Portfolio Offerings

MILFORD, Mass.--(BUSINESS WIRE)-- #CQA--The BioAccord System with ACQUITY Premier simplifies CQA monitoring of biologics by improving analyte recovery and assay-to-assay reproducibility.

Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals

News for Waters Stock (WAT)